Janssen Pharmaceuticals, Inc. is a major American pharmaceutical company and one of the pharmaceutical companies within the Janssen Pharmaceutical Companies of Johnson & Johnson. Headquartered in Titusville, New Jersey, USA, the company operates as part of the global healthcare enterprise of Johnson & Johnson, one of the world's largest and most diversified healthcare organizations. Janssen's roots trace back to the pioneering work of Dr. Paul Janssen, a Belgian physician and researcher who founded Janssen Pharmaceutica in 1953 and became one of the most prolific drug innovators of the 20th century. Johnson & Johnson acquired Janssen in 1961, and today the Janssen name represents the pharmaceutical division of the broader J&J family.
The company is committed to addressing some of the most significant unmet medical needs of our time. Its mission centers on transforming the trajectory of complex diseases through innovative science, working to prevent, treat, cure, and ultimately stop illnesses across a range of therapeutic areas.
Therapeutic Focus Areas
Janssen concentrates its research, development, and commercialization efforts across several core therapeutic areas where the burden of disease is high and where scientific breakthroughs can make a meaningful difference:
Immunology
Janssen develops treatments for immune-mediated inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, psoriasis, inflammatory bowel disease (Crohn's disease and ulcerative colitis), and other autoimmune conditions.
Oncology
The company invests heavily in cancer research, targeting hematologic malignancies such as multiple myeloma and certain leukemias, as well as solid tumors including prostate cancer and bladder cancer.
Neuroscience
Janssen addresses conditions affecting the brain and nervous system, including schizophrenia, bipolar disorder, major depressive disorder, treatment-resistant depression, and Alzheimer's disease.
Infectious Diseases and Vaccines
The company works on solutions for viral and bacterial diseases, including HIV, hepatitis, tuberculosis, and respiratory illnesses. Janssen was notably involved in developing a COVID-19 vaccine.
Cardiovascular and Metabolism
Janssen develops therapies for cardiovascular disease, thrombosis, diabetes, and related metabolic disorders.
Pulmonary Hypertension
The company offers treatments addressing pulmonary arterial hypertension, a rare and progressive disease affecting the blood vessels of the lungs.
Key Products
Janssen markets a broad portfolio of prescription medications across its therapeutic areas. Notable products associated with Janssen Pharmaceuticals include:
- Stelara (ustekinumab) — a biologic treatment used for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
- Tremfya (guselkumab) — used to treat plaque psoriasis and psoriatic arthritis.
- Simponi and Simponi Aria (golimumab) — biologic therapies for various inflammatory arthritis conditions.
- Remicade (infliximab) — a treatment for multiple autoimmune conditions.
- Darzalex (daratumumab) — a treatment for multiple myeloma.
- Imbruvica (ibrutinib) — used in the treatment of certain blood cancers.
- Erleada (apalutamide) and Zytiga (abiraterone acetate) — treatments for prostate cancer.
- Invega, Invega Sustenna, Invega Trinza, and Risperdal — antipsychotic medications for schizophrenia and related disorders.
- Spravato (esketamine) — a nasal spray for treatment-resistant depression.
- Xarelto (rivaroxaban) — an anticoagulant used to prevent and treat blood clots.
- Invokana (canagliflozin) — a treatment for type 2 diabetes.
- Uptravi, Opsumit, and Tracleer — medications for pulmonary arterial hypertension.
- Edurant, Prezista, and Symtuza — antiretroviral medications used in HIV treatment.
Research and Development
Janssen maintains a strong commitment to scientific innovation, investing substantial resources into research and development. The company collaborates with academic institutions, biotechnology firms, government agencies, and patient advocacy organizations to advance new therapies. Its research pipeline reflects a focus on precision medicine, biologics, small molecules, cell and gene therapies, and vaccines. Janssen leverages advanced technologies and data science to accelerate discovery and improve the way diseases are understood and treated.
The company's research operations span multiple facilities globally, engaging in early discovery through late-stage clinical development. Janssen emphasizes translational science, aiming to move promising discoveries from the laboratory to clinical application efficiently.
Corporate Values and Commitments
As part of Johnson & Johnson, Janssen operates under the guidance of the J&J Credo, a long-standing statement of values that prioritizes responsibility to patients, healthcare providers, employees, communities, and shareholders. The company places significant emphasis on patient access to medicines, transparency in pricing and clinical trial data, and ethical conduct in all its operations.
Janssen is also engaged in global health initiatives, working to combat diseases that disproportionately affect underserved populations, including tuberculosis and HIV in developing regions. The company participates in partnerships aimed at expanding access to medicines and building healthcare capacity in low- and middle-income countries.
Position in the Industry
Janssen Pharmaceuticals stands as one of the most significant contributors to the pharmaceutical industry, both in the United States and worldwide. Its combination of scientific expertise, financial strength as part of Johnson & Johnson, and a diverse product portfolio positions it as a leader in developing innovative treatments for serious and often life-threatening diseases. The company continues to be recognized for its historical legacy of drug discovery, tracing back to its founder Dr. Paul Janssen, whose contributions to medicine helped shape the modern pharmaceutical landscape.
Through its ongoing research, development of new therapies, and commitment to patient-centered healthcare, Janssen Pharmaceuticals remains dedicated to its overarching goal of creating a future where disease is a thing of the past.
